<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02858479</url>
  </required_header>
  <id_info>
    <org_study_id>1308174</org_study_id>
    <secondary_id>2013-A01791-44</secondary_id>
    <nct_id>NCT02858479</nct_id>
  </id_info>
  <brief_title>Structural and Functional Brain Reorganization in Neuropathic Pain. Influences of the Loss of Sensitivity and the Atrophy Cortical on Activations Due to Stimulation Allodynic</brief_title>
  <acronym>ALLO</acronym>
  <official_title>Structural and Functional Brain Reorganization in Neuropathic Pain. Influences of the Loss of Sensitivity and the Atrophy Cortical on Activations Due to Stimulation Allodynic</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Hospitalier Universitaire de Saint Etienne</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Centre Hospitalier Universitaire de Saint Etienne</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Neuropathic pain is a medical condition involving allodynia (painful perceptions in response&#xD;
      to stimuli that normally are not) and spontaneous pain (occurring at rest, without&#xD;
      stimulation).&#xD;
&#xD;
      This pain is secondary to nervous system injury affecting the sensory system. The lesion is&#xD;
      either at the nerve endings of the spinal cord or brain. It induces a loss of sensitivity and&#xD;
      reorganization of brain activity.&#xD;
&#xD;
      Previous studies in functional neuroimaging have focused on brain areas activated during&#xD;
      allodynic stimuli compared to non-painful stimuli. The abnormalities have been reported, but&#xD;
      it was not possible to conclude formally.&#xD;
&#xD;
      The objective of this study is to understand the brain dysfunction that induces allodynic&#xD;
      pain considering the deafferentation of each patient and possible cortical losses.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    failure to recruit&#xD;
  </why_stopped>
  <start_date type="Actual">March 25, 2016</start_date>
  <completion_date type="Actual">February 11, 2019</completion_date>
  <primary_completion_date type="Actual">February 11, 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>the deafferentation rate</measure>
    <time_frame>at baseline</time_frame>
    <description>the deafferentation rate measured with thermo-test</description>
  </primary_outcome>
  <primary_outcome>
    <measure>gray matter rate</measure>
    <time_frame>at baseline</time_frame>
    <description>gray matter rate measured with MRI scan</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Analysis pain</measure>
    <time_frame>at baseline</time_frame>
    <description>Measured by visual analogue scale (0 to 10)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">41</enrollment>
  <condition>Neuropathic Pain</condition>
  <arm_group>
    <arm_group_label>patients with pain allodynic peripheral</arm_group_label>
    <arm_group_type>Other</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>patients with pain allodynic central</arm_group_label>
    <arm_group_type>Other</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>stimulation on painful area (area allodynic)</intervention_name>
    <description>these stimulations will be performed either with a brush, with a cold block or with forced air (cold air or air to ambient temp) : calibrated to induce pain bearable.&#xD;
stimulations for 6 seconds</description>
    <arm_group_label>patients with pain allodynic central</arm_group_label>
    <arm_group_label>patients with pain allodynic peripheral</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>same stimulation on non-painful area</intervention_name>
    <description>these stimulations will be performed either with a brush, with a cold block or with forced air (cold air or air to ambient temp) : calibrated to induce pain bearable.&#xD;
stimulations for 6 seconds</description>
    <arm_group_label>patients with pain allodynic central</arm_group_label>
    <arm_group_label>patients with pain allodynic peripheral</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>MRI scan</intervention_name>
    <description>2 sessions for 10 minutes :&#xD;
11 controls stimulations for 6 s each spaced 20 s without stimulation.&#xD;
11 allodynic stimulations for 6 s each spaced 20 s without stimulation.</description>
    <arm_group_label>patients with pain allodynic central</arm_group_label>
    <arm_group_label>patients with pain allodynic peripheral</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  with neuropathic pain&#xD;
&#xD;
          -  in the case of central lesions, the lesion must be unique and small&#xD;
&#xD;
          -  treatment not stable opioid for one week&#xD;
&#xD;
          -  consent signed&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  severe psychiatric history&#xD;
&#xD;
          -  presence of an evolutive lesion, expansive, cancerous or tumorous underlying&#xD;
&#xD;
          -  patient needing of opioid therapy&#xD;
&#xD;
          -  contraindication at MRI scan&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Roland PEYRON, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>CHU de SAINT-ETIENNE</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>CHU de SAINT-ETIENNE</name>
      <address>
        <city>Saint-etienne</city>
        <zip>42000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>September 2020</verification_date>
  <study_first_submitted>August 1, 2016</study_first_submitted>
  <study_first_submitted_qc>August 3, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 8, 2016</study_first_posted>
  <last_update_submitted>September 24, 2020</last_update_submitted>
  <last_update_submitted_qc>September 24, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">September 28, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neuralgia</mesh_term>
    <mesh_term>Atrophy</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

